Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Rating of “Moderate Buy” by Brokerages

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has received an average rating of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $69.3333.

Several research analysts recently commented on TARS shares. Zacks Research raised shares of Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, September 5th. HC Wainwright boosted their target price on shares of Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the company a “neutral” rating in a report on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Wednesday, October 8th.

Insider Transactions at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, Director William J. Phd Link sold 27,116 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $57.00, for a total value of $1,545,612.00. Following the completion of the transaction, the director owned 143,332 shares of the company’s stock, valued at approximately $8,169,924. The trade was a 15.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bobak R. Azamian sold 6,000 shares of the company’s stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $55.37, for a total transaction of $332,220.00. Following the sale, the chief executive officer directly owned 812,106 shares of the company’s stock, valued at $44,966,309.22. The trade was a 0.73% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 39,116 shares of company stock valued at $2,177,832. 8.97% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Paradigm Biocapital Advisors LP lifted its position in Tarsus Pharmaceuticals by 3.1% in the first quarter. Paradigm Biocapital Advisors LP now owns 2,610,197 shares of the company’s stock worth $134,086,000 after buying an additional 78,301 shares during the last quarter. Vanguard Group Inc. grew its holdings in Tarsus Pharmaceuticals by 5.3% during the 1st quarter. Vanguard Group Inc. now owns 2,226,595 shares of the company’s stock worth $114,380,000 after acquiring an additional 111,433 shares in the last quarter. Lord Abbett & CO. LLC grew its holdings in Tarsus Pharmaceuticals by 4.0% during the 1st quarter. Lord Abbett & CO. LLC now owns 1,331,701 shares of the company’s stock worth $68,409,000 after acquiring an additional 51,714 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in Tarsus Pharmaceuticals by 25.1% in the third quarter. Assenagon Asset Management S.A. now owns 1,247,954 shares of the company’s stock valued at $74,166,000 after purchasing an additional 250,367 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Tarsus Pharmaceuticals by 8.0% in the second quarter. Geode Capital Management LLC now owns 934,420 shares of the company’s stock valued at $37,859,000 after purchasing an additional 68,986 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Trading Down 3.3%

TARS stock opened at $66.06 on Monday. The company has a market capitalization of $2.79 billion, a PE ratio of -28.35 and a beta of 0.81. Tarsus Pharmaceuticals has a one year low of $38.51 and a one year high of $76.81. The company’s 50 day moving average price is $60.38 and its two-hundred day moving average price is $49.73. The company has a debt-to-equity ratio of 0.22, a quick ratio of 5.21 and a current ratio of 5.26.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.15). The business had revenue of $102.66 million for the quarter, compared to analysts’ expectations of $95.81 million. Tarsus Pharmaceuticals had a negative return on equity of 32.36% and a negative net margin of 31.13%. As a group, analysts predict that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.